|
1
|
Hussain S, Jha S, Berger E, Molander L, Sevastianova V, Sheybani Z, Espinosa AS, Elmahdy A, Al-Awar A, Kakaei Y, Kalani M, Zulfaj E, Nejat A, Jha A, Pylova T, Krasnikova M, Andersson EA, Omerovic E, Redfors B. Comparative Analysis of Plasma Protein Dynamics in Women with ST-Elevation Myocardial Infarction and Takotsubo Syndrome. Cells 2024; 13:1764. [PMID: 39513871 PMCID: PMC11545104 DOI: 10.3390/cells13211764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2024] [Revised: 10/08/2024] [Accepted: 10/23/2024] [Indexed: 11/16/2024] Open
Abstract
BACKGROUND ST-elevation myocardial infarction (STEMI) and Takotsubo syndrome (TS) are two distinct cardiac conditions that both result in sudden loss of cardiac dysfunction and that are difficult to distinguish clinically. This study compared plasma protein changes in 24 women with STEMI and 12 women with TS in the acute phase (days 0-3 post symptom onset) and the stabilization phase (days 7, 14, and 30) to examine the molecular differences between these conditions. METHODS Plasma proteins from STEMI and TS patients were extracted during the acute and stabilization phases and analyzed via quantitative proteomics. Differential expression and functional significance were assessed. Data are accessible on ProteomeXchange, ID PXD051367. RESULTS During the acute phase, STEMI patients showed higher levels of myocardial inflammation and tissue damage proteins compared to TS patients, along with reduced tissue repair and anti-inflammatory proteins. In the stabilization phase, STEMI patients exhibited ongoing inflammation and disrupted lipid metabolism. Notably, ADIPOQ was consistently downregulated in STEMI patients in both phases. When comparing the acute to the stabilization phase, STEMI patients showed increased inflammatory proteins and decreased structural proteins. Conversely, TS patients showed increased proteins involved in inflammation and the regulatory response to counter excessive inflammation. Consistent protein changes between the acute and stabilization phases in both conditions, such as SAA2, CRP, SAA1, LBP, FGL1, AGT, MAN1A1, APOA4, COMP, and PCOLCE, suggest shared underlying pathophysiological mechanisms. CONCLUSIONS This study presents protein changes in women with STEMI or TS and identifies ADIPOQ, SAA2, CRP, SAA1, LBP, FGL1, AGT, MAN1A1, APOA4, COMP, and PCOLCE as candidates for further exploration in both therapeutic and diagnostic contexts.
Collapse
Affiliation(s)
- Shafaat Hussain
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Sandeep Jha
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
- Department of Cardiology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden
| | - Evelin Berger
- Proteomics Core Facility, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden;
| | - Linnea Molander
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Valentyna Sevastianova
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Zahra Sheybani
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Aaron Shekka Espinosa
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Ahmed Elmahdy
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Amin Al-Awar
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Yalda Kakaei
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Mana Kalani
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Ermir Zulfaj
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
| | - Amirali Nejat
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
| | - Abhishek Jha
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Tetiana Pylova
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Maryna Krasnikova
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Erik Axel Andersson
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Elmir Omerovic
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Department of Cardiology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden
| | - Björn Redfors
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
- Department of Cardiology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden
| |
Collapse
|
|
2
|
Sun J, Xu J, Liu Y, Xu X, Zhang S, Hao Y, Lin Y, Han Y, Li F, Yuan H. Proteomic and metabolomic analyses reveal the novel targets of spermine for alleviating diabetic cardiomyopathy in type II diabetic mice. Front Cardiovasc Med 2022; 9:1022861. [PMID: 36312255 PMCID: PMC9614018 DOI: 10.3389/fcvm.2022.1022861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 09/23/2022] [Indexed: 11/13/2022] Open
Abstract
Diabetic cardiomyopathy (DCM) is one of the most serious complications of diabetes. Recent cardiology studies suggest that spermine has a cardioprotective effect. Here, we used proteomic and metabolomic analyses to reveal the underlying research targets in a type II diabetic (T2D) mouse model treated with spermine. Left ventricular tissues from nine mice (Control group, three; T2D group, three; T2D+SP group, three) were excised and analyzed. Quantitative analysis of the global proteome and metabolome was performed using the 4D label-free technique and untargeted metabolomics, respectively, and differentially expressed proteins (DEPs) and metabolites were used to perform bioinformatic analyses. A total of 169 DEPs were identified in T2D/Control group, including 115 upregulated and 54 downregulated proteins. Furthermore, 16 DEPs were identified in T2D+SP/T2D group, where these DEPs were found highly enriched in the cellular, metabolic processes, biological regulation, response to stimulus, and immune system process. The results of association analysis between proteomics and metabolomics showed that SP could affect the production of 51 metabolites by regulating the expression of 16 DEPs in the T2D+SP/T2D group. We also found that PRKG1 was closely related to the expressions of 10 overlapping metabolites between db/db and SP-treated mice. Our findings provide insights into the underlying mechanisms for DCM and suggest the potential applicability of utilizing spermine on protecting against DCM-associated cardiac function deterioration.
Collapse
Affiliation(s)
- Jian Sun
- School of Basic Medical Sciences, Mudanjiang Medical University, Mudanjiang, China
| | - Jiyu Xu
- School of Medical Imaging, Mudanjiang Medical University, Mudanjiang, China
| | - Yong Liu
- Research Department, Animal Research Institute, Mudanjiang Medical University, Mudanjiang, China
| | - Xiaoyi Xu
- The First Clinical School of Medicine, Mudanjiang Medical University, Mudanjiang, China
| | - Shumin Zhang
- School of Stomatology, Mudanjiang Medical University, Mudanjiang, China
| | - Yankun Hao
- School of Basic Medical Sciences, Mudanjiang Medical University, Mudanjiang, China
| | - Yitong Lin
- School of Basic Medical Sciences, Mudanjiang Medical University, Mudanjiang, China
| | - Yue Han
- School of Basic Medical Sciences, Mudanjiang Medical University, Mudanjiang, China
| | - Feiya Li
- Department of Laboratory Medicine and Pathobiology, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
| | - Hui Yuan
- School of Basic Medical Sciences, Mudanjiang Medical University, Mudanjiang, China,School of Stomatology, Mudanjiang Medical University, Mudanjiang, China,*Correspondence: Hui Yuan
| |
Collapse
|
|
3
|
Xie S, Li Q, Luk AOY, Lan HY, Chan PKS, Bayés-Genís A, Chan FKL, Fung E. Major Adverse Cardiovascular Events and Mortality Prediction by Circulating GDF-15 in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Biomolecules 2022; 12:934. [PMID: 35883490 PMCID: PMC9312922 DOI: 10.3390/biom12070934] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 06/25/2022] [Accepted: 06/28/2022] [Indexed: 12/10/2022] Open
Abstract
Background: Growth differentiation factor 15 (GDF-15) is a homeostatic cytokine that regulates neural and cardio-metabolic functions, and its release is increased in response to stress, injury, and inflammation. In patients with coronary artery disease and heart failure (HF), three separate meta-analyses have found that elevated circulating GDF-15 was predictive of major adverse cardiovascular events (MACE), but none has evaluated its effects on incident MACE including HF and mortality hazard in type 2 diabetes. Methods: MEDLINE, EMBASE, and Scopus databases were queried. Articles that met the predefined eligibility criteria, including prospective studies that reported adjusted hazard ratios (aHRs), were selected according to the Cochrane Handbook and PRISMA guidelines. Study endpoints were (1) MACE including HF, and (2) all-cause mortality. Different GDF-15 concentration measurements were harmonized using a validated mathematical approach to express log2-transformed values in per standard deviation (SD). Study heterogeneity (I2), quality, and bias were assessed. Results: 19354 patients in 8 prospective studies were included. In 7 studies that reported 4247 MACE among 19200 participants, the incident rate was 22.1% during a median follow-up of 5.6 years. It was found that four of eight studies included HF decompensation or hospitalization as a component of MACE. In 5 studies that reported all-cause mortality, 1893 of 13223 patients died, at an incidence rate of 15.1% over 5.0 years. Of note, each 1 SD increase of log2[GDF-15] was associated with aHRs of 1.12 (1.09−1.15, I2 = 5%, p < 0.000001) and 1.27 (1.11−1.46, I2 = 86%, p = 0.00062) and for MACE and all-cause mortality, respectively. Conclusion: Elevated circulating level of GDF-15 was robustly predictive of MACE in patients with T2D but its prognostic significance in the prediction of mortality requires further studies.
Collapse
Affiliation(s)
- Suyi Xie
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; (S.X.); (Q.L.); (A.O.Y.L.); (H.-Y.L.); (F.K.L.C.)
- Laboratory for Heart Failure + Circulation Research, Li Ka Shing Institute of Health Sciences, and Gerald Choa Cardiac Research Centre, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
| | - Qi Li
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; (S.X.); (Q.L.); (A.O.Y.L.); (H.-Y.L.); (F.K.L.C.)
- Laboratory for Heart Failure + Circulation Research, Li Ka Shing Institute of Health Sciences, and Gerald Choa Cardiac Research Centre, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- Heart Center of Henan Provincial People’s Hospital, Department of Cardiology of Central China Fuwai Hospital, Henan Key Laboratory for Coronary Heart Disease Prevention and Control, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou 450003, China
| | - Andrea O. Y. Luk
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; (S.X.); (Q.L.); (A.O.Y.L.); (H.-Y.L.); (F.K.L.C.)
- Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, China
- Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
| | - Hui-Yao Lan
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; (S.X.); (Q.L.); (A.O.Y.L.); (H.-Y.L.); (F.K.L.C.)
- Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
- CARE Programme, Lui Che Woo Institute of Innovative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
| | - Paul K. S. Chan
- Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China;
- Stanley Ho Centre for Emerging Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
| | - Antoni Bayés-Genís
- iCor, Hospital Universitari Germans Trias i Pujol de Badalona, 08916 Badalona, Spain;
- ICREC Research Program, Germans Trias i Pujol Health Science Research Institute, Can Ruti Campus, 08916 Badalona, Spain
- Department of Medicine, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain
- CIBER Cardiovascular, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Francis K. L. Chan
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; (S.X.); (Q.L.); (A.O.Y.L.); (H.-Y.L.); (F.K.L.C.)
- CARE Programme, Lui Che Woo Institute of Innovative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- Centre for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
| | - Erik Fung
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; (S.X.); (Q.L.); (A.O.Y.L.); (H.-Y.L.); (F.K.L.C.)
- Laboratory for Heart Failure + Circulation Research, Li Ka Shing Institute of Health Sciences, and Gerald Choa Cardiac Research Centre, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- CARE Programme, Lui Che Woo Institute of Innovative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, St Mary’s Campus, Imperial College London, London W2 1PG, UK
| |
Collapse
|
|
4
|
Balashkevich N, Kazymov M, Syzdykbayev M, Adylova A. Molecular basis of acute coronary syndrome. JOURNAL OF RESEARCH IN MEDICAL SCIENCES : THE OFFICIAL JOURNAL OF ISFAHAN UNIVERSITY OF MEDICAL SCIENCES 2022; 27:40. [PMID: 35968216 PMCID: PMC9374151 DOI: 10.4103/jrms.jrms_695_21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 12/08/2021] [Accepted: 01/24/2022] [Indexed: 11/04/2022]
Abstract
Cardiovascular diseases (CVD) comprise of various heart and blood vessels-related diseases. Acute coronary syndrome (ACS) is one of them. Basic researchers and cardiologists have witnessed landmark developments related to ACS and despite rapid refinement in our understanding; scientists are seeking answers for more questions. Scientists have mapped wide ranging proteins and intricate protein networks which play central role in the pathogenesis in ACS. In this review, we have attempted to summarize underlying causes of ACS. Better understanding of the disease pathology will enable us to get a step closer to an effective clinical management.
Collapse
Affiliation(s)
| | - Maxut Kazymov
- Department of Family Medicine, Semey Medical University, Semey, Kazakhstan
| | - Marat Syzdykbayev
- Department of Anesthesiology, Reanimatology and Narcology, Semey Medical University, Semey, Kazakhstan
| | - Aima Adylova
- Department of Public Health, Kazakhstan School of Public Health, Almaty, Kazakhstan,Address for correspondence: Dr. Aima Adylova, Kazakhstan School of Public Health, Almaty, Kazakhstan. E-mail:
| |
Collapse
|
|
5
|
Ronsein GE, Vaisar T, Davidson WS, Bornfeldt KE, Probstfield JL, O'Brien KD, Zhao XQ, Heinecke JW. Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. Arterioscler Thromb Vasc Biol 2021; 41:2330-2341. [PMID: 34134520 DOI: 10.1161/atvbaha.121.316278] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
| | - Tomas Vaisar
- Department of Medicine, University of Washington, Seattle (T.V., K.E.B., J.L.P., K.D.O., X.-Q.Z., J.W.H.)
| | - W Sean Davidson
- Department of Pathology and Laboratory Medicine, University of Cincinnati, OH (W.S.D.)
| | - Karin E Bornfeldt
- Department of Medicine, University of Washington, Seattle (T.V., K.E.B., J.L.P., K.D.O., X.-Q.Z., J.W.H.)
| | - Jeffrey L Probstfield
- Department of Medicine, University of Washington, Seattle (T.V., K.E.B., J.L.P., K.D.O., X.-Q.Z., J.W.H.)
| | - Kevin D O'Brien
- Department of Medicine, University of Washington, Seattle (T.V., K.E.B., J.L.P., K.D.O., X.-Q.Z., J.W.H.)
| | - Xue-Qiao Zhao
- Department of Medicine, University of Washington, Seattle (T.V., K.E.B., J.L.P., K.D.O., X.-Q.Z., J.W.H.)
| | - Jay W Heinecke
- Department of Medicine, University of Washington, Seattle (T.V., K.E.B., J.L.P., K.D.O., X.-Q.Z., J.W.H.)
| |
Collapse
|
|
6
|
Zhang K, Zheng J, Chen Y, Dong J, Li Z, Chiang YP, He M, Huang Q, Tang H, Jiang XC. Inducible phospholipid transfer protein deficiency ameliorates atherosclerosis. Atherosclerosis 2021; 324:9-17. [PMID: 33798923 DOI: 10.1016/j.atherosclerosis.2021.03.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Revised: 02/23/2021] [Accepted: 03/11/2021] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND AIMS Atherosclerosis progression and regression studies are related to its prevention and treatment. Although we have gained extensive knowledge on germline phospholipid transfer protein (PLTP) deficiency, the effect of inducible PLTP deficiency in atherosclerosis remains unexplored. METHODS We generated inducible PLTP (iPLTP)-knockout (KO) mice and measured their plasma lipid levels after feeding a normal chow or a Western-type diet. Adenovirus associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9) was used to induce hypercholesterolemia in the mice. Collars were placed around the common carotid arteries, and atherosclerosis progression and regression in the carotid arteries and aortic roots were evaluated. RESULTS On a normal chow diet, iPLTP-KO mice exhibited decreased cholesterol, phospholipid, apoA-I, and apoB levels compared with control mice. Furthermore, the overall amount of high-density lipoprotein (HDL) particles was reduced in these mice, but this effect was more profound for larger HDL particles. On a Western-type diet, iPLTP-KO mice again exhibited reduced levels of all tested lipids, even though the basal lipid levels were increased. Additionally, these mice displayed significantly reduced atherosclerotic plaque sizes with increased plaque stability. Importantly, inducible PLTP deficiency significantly ameliorated atherosclerosis by reducing the size of established plaques and the number of macrophages in the plaques without causing lipid accumulation in the liver. CONCLUSIONS Induced PLTP deficiency in adult mice reduces plasma total cholesterol and triglycerides, prevents atherosclerosis progression, and promotes atherosclerosis regression. Thus, PLTP inhibition is a promising therapeutic approach for atherosclerosis.
Collapse
Affiliation(s)
- Ke Zhang
- Department of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA; Department of Emergency, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Jiao Zheng
- Department of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA; Beijing University of Chinese Medicine, Beijing, China
| | | | | | - Zhiqiang Li
- Department of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA; Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System, Brooklyn, New York, USA
| | - Yeun-Po Chiang
- Department of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA
| | - Mulin He
- Department of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA
| | | | | | - Xian-Cheng Jiang
- Department of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA; Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System, Brooklyn, New York, USA.
| |
Collapse
|
|
7
|
Jiang XC, Yu Y. The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis. Curr Atheroscler Rep 2021; 23:9. [PMID: 33496859 DOI: 10.1007/s11883-021-00907-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/13/2021] [Indexed: 12/11/2022]
Abstract
PURPOSE OF REVIEW Phospholipid transfer protein (PLTP), a member of lipid transfer protein family, is an important protein involved in lipid metabolism in the circulation. This article reviews recent PLTP research progresses, involving lipoprotein metabolism and atherogenesis. RECENT FINDINGS PLTP activity influences atherogenic and anti-atherogenic lipoprotein levels. Human serum PLTP activity is a risk factor for human cardiovascular disease and is an independent predictor of all-cause mortality. PLTP deficiency reduces VLDL and LDL levels and attenuates atherosclerosis in mouse models, while PLTP overexpression exerts an opposite effect. Both PLTP deficiency and overexpression result in reduction of HDL which has different size, inflammatory index, and lipid composition. Moreover, although both PLTP deficiency and overexpression reduce cholesterol efflux capacity, but this effect has no impact in macrophage reverse cholesterol transport in mice. Furthermore, PLTP activity is related with metabolic syndrome, thrombosis, and inflammation. PLTP could be target for the treatment of dyslipidemia and atherosclerosis, although some potential off-target effects should be noted.
Collapse
Affiliation(s)
- Xian-Cheng Jiang
- Department of Cell Biology, SUNY Downstate Health Sciences University, 450 Clarkson Ave, Brooklyn, NY, USA.
| | - Yang Yu
- Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, 271000, People's Republic of China
| |
Collapse
|
|
8
|
Impact of Phospholipid Transfer Protein in Lipid Metabolism and Cardiovascular Diseases. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2020; 1276:1-13. [PMID: 32705590 DOI: 10.1007/978-981-15-6082-8_1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
PLTP plays an important role in lipoprotein metabolism and cardiovascular disease development in humans; however, the mechanisms are still not completely understood. In mouse models, PLTP deficiency reduces cardiovascular disease, while its overexpression induces it. Therefore, we used mouse models to investigate the involved mechanisms. In this chapter, the recent main progresses in the field of PLTP research are summarized, and our focus is on the relationship between PLTP and lipoprotein metabolism, as well as PLTP and cardiovascular diseases.
Collapse
|
|
9
|
Wang W, Li Z, Zheng Y, Yan M, Cui Y, Jiang J. Circulating microRNA-92a level predicts acute coronary syndrome in diabetic patients with coronary heart disease. Lipids Health Dis 2019; 18:22. [PMID: 30670045 PMCID: PMC6343303 DOI: 10.1186/s12944-019-0964-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2018] [Accepted: 01/06/2019] [Indexed: 12/24/2022] Open
Abstract
PURPOSE This study was designed to explore the value of monitoring miR-92a in T2DM patients with coronary heart disease (CHD). MATERIALS AND METHODS 40 ACS patients with prior history of CHD and diabetes while the onset time of diabetes preceded that of CHD by more than 2 years were enrolled as the DACS group(diabetic ACS group). 40 ACS subjects who had had a definite diagnosis of CHD for more than 2 years with no history of T2DM were recuited as the CACS group(chronic CHD with ACS group). All enrolled subjects from DACS and CACS group came from an emergency basis and diagnosed with ACS by coronary angiography. Another 68 age- and sex-matched volunteers with chronic stable CHD without diabetes history were assigned as the control group (CHD group). We examined the serum levels of miR-92a and analyzed their correlations with blood pressure, glucose level, and lipid level. RESULTS The levels of miR-92a were significantly elevated in the DACS group compared with those of the CACS and CHD groups. Multivariate analysis showed that miR-92a, systolic blood pressure (SBP), and glycosylated hemoglobin (HbA1c) were significantly related to ACS events in patients with T2DM. Forward stepwise binary logistic regression analysis identified miR-92a as an independent predictive factor for ACS events in the patients with T2DM. CONCLUSION An elevated circulating miR-92a level was associated with an increased risk of ACS in CHD patients with T2DM. Thus the level of miR-92a, especially combined with elevated SBP and HbA1c, may be helpful in the detection of ACS in patients with T2DM.
Collapse
Affiliation(s)
- Wenyi Wang
- International Medical Center, Tianjin First Central Hospital, No. 24 of Fukang Road, Nankai District, Tianjin, 300192, China
| | - Zhigang Li
- International Medical Center, Tianjin First Central Hospital, No. 24 of Fukang Road, Nankai District, Tianjin, 300192, China.
| | - Yashu Zheng
- International Medical Center, Tianjin First Central Hospital, No. 24 of Fukang Road, Nankai District, Tianjin, 300192, China
| | - Meiling Yan
- Pharmacy Department, Tianjin First Central Hospital, Tianjin, China
| | - Yameng Cui
- International Medical Center, Tianjin First Central Hospital, No. 24 of Fukang Road, Nankai District, Tianjin, 300192, China
| | - Jiechun Jiang
- Medical Laboratory, Tianjin First Central Hospital, Tianjin, China
| |
Collapse
|
|
10
|
p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease. Life Sci 2018; 215:64-72. [DOI: 10.1016/j.lfs.2018.10.051] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Revised: 10/17/2018] [Accepted: 10/25/2018] [Indexed: 12/19/2022]
|
|
11
|
Zhao XM, Wang Y, Yu Y, Jiang H, Babinska A, Chen XY, He KG, Min XD, Han JJ, Yang CX, Deng K, Xue J, Zhang X, Song GH, Qin SC, Jiang XC. Plasma Phospholipid Transfer Protein Promotes Platelet Aggregation. Thromb Haemost 2018; 118:2086-2097. [PMID: 30419596 DOI: 10.1055/s-0038-1675228] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
It remains unclear whether plasma phospholipid transfer protein (PLTP) is involved in hyper-coagulation or hypo-coagulation. This study investigated the direct effect of PLTP on platelet aggregation and the underlying mechanism. Washed platelets from humans or mice and mouse platelet-rich plasma and human recombinant PLTP were isolated. PLTP is present in human platelets. We assessed adenosine diphosphate (ADP)-, collagen- and thrombin-induced platelet aggregation, phosphatidylserine externalization and photothrombosis-induced cerebral infarction in mice. PLTP over-expression increased platelet aggregation, while PLTP deficiency had the opposing reaction. Human recombinant PLTP increased both mouse and human platelet aggregation in a dose-dependent manner. Phosphatidylserine externalization provides a water/lipid surface for the interaction of coagulation factors, which accelerates thrombosis. Compared with wild-type controls, platelets from PLTP transgenic mice had significantly more phosphatidylserine on the exterior surface of the plasma membrane, whereas platelets from PLTP-deficient mice had significantly less phosphatidylserine on the surface, thus PLTP influences fibrinogen binding on the plasma membrane. Moreover, recombinant PLTP together with ADP significantly increased phosphatidylserine exposure on the plasma membrane of PLTP-deficient platelets, thereby increasing fibrinogen binding. PLTP over-expression significantly accelerated the incidence of photothrombosis-induced infarction in mice, whereas PLTP deficiency significantly reduced the frequency of infarction. We concluded that PLTP promotes phosphatidylserine externalization at the plasma membrane of platelets and accelerates ADP- or collagen-induced platelet aggregation. This effect plays an important role in the initiation of thrombin generation and platelet aggregation under sheer stress conditions. Thus, PLTP is involved in hyper-coagulation. Therefore, PLTP inhibition could be a novel approach for countering thrombosis.
Collapse
Affiliation(s)
- Xiao-Min Zhao
- The Institute of Atherosclerosis, Taishan Medical University, Taian, China
| | - Yun Wang
- The Institute of Atherosclerosis, Taishan Medical University, Taian, China
| | - Yang Yu
- The Institute of Atherosclerosis, Taishan Medical University, Taian, China
| | - Hui Jiang
- Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York, United States
| | - Anna Babinska
- Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York, United States
| | - Xiu-Yu Chen
- The Institute of Atherosclerosis, Taishan Medical University, Taian, China
| | - Ke-Gui He
- The Institute of Atherosclerosis, Taishan Medical University, Taian, China
| | - Xiang-Dong Min
- The Institute of Atherosclerosis, Taishan Medical University, Taian, China
| | - Ji-Ju Han
- The Institute of Atherosclerosis, Taishan Medical University, Taian, China
| | - Chen-Xi Yang
- The Institute of Atherosclerosis, Taishan Medical University, Taian, China
| | - Kevin Deng
- Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York, United States
| | - Jing Xue
- Hebei Collaborative Innovation Center for Cardio-cerebrovascular Disease, Hebei Key Laboratory of Vascular Homeostasis, Shijiazhuang, China
| | - Xiangjian Zhang
- Hebei Collaborative Innovation Center for Cardio-cerebrovascular Disease, Hebei Key Laboratory of Vascular Homeostasis, Shijiazhuang, China
| | - Guo-Hua Song
- The Institute of Atherosclerosis, Taishan Medical University, Taian, China
| | - Shu-Cun Qin
- The Institute of Atherosclerosis, Taishan Medical University, Taian, China
| | - Xian-Cheng Jiang
- Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York, United States.,Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System, Brooklyn, New York, United States
| |
Collapse
|
|
12
|
Yu Y, Lei X, Jiang H, Li Z, Creemers JWM, Zhang M, Qin S, Jin W, Jiang X. Prodomain of Furin Promotes Phospholipid Transfer Protein Proteasomal Degradation in Hepatocytes. J Am Heart Assoc 2018; 7:e008526. [PMID: 29680823 PMCID: PMC6015287 DOI: 10.1161/jaha.118.008526] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Accepted: 03/22/2018] [Indexed: 12/21/2022]
Abstract
BACKGROUND Phospholipid transfer protein (PLTP) is one of the major modulators of lipoprotein metabolism and atherosclerosis development; however, little is known about the regulation of PLTP. The effect of hepatic prodomain of furin (profurin) expression on PLTP processing and function is investigated. METHODS AND RESULTS We used adenovirus expressing profurin in mouse liver to evaluate PLTP activity, mass, and plasma lipid levels. We coexpressed PLTP and profurin in human hepatoma cell line cells and studied their interaction. We found profurin expression significantly reduced plasma lipids, plasma PLTP activity, and mass in all tested mouse models, compared with controls. Moreover, the expression of profurin dramatically reduced liver PLTP activity and protein level. We further explored the mechanism using in vivo and ex vivo approaches. We found that profurin can interact with intracellular PLTP and promote its ubiquitination and proteasomal degradation, resulting in less PLTP secretion from the hepatocytes. Furin does not cleave PLTP; instead, it forms a complex with PLTP, likely through its prodomain. CONCLUSIONS Our study reveals that hepatic PLTP protein is targeted for proteasomal degradation by profurin expression, which could be a novel posttranslational mechanism underlying PLTP regulation.
Collapse
Affiliation(s)
- Yang Yu
- Department of Cell BiologyState University of New York Downstate Medical CenterBrooklynNY
- Key Laboratory of Atherosclerosis in Universities of Shandong and Institute of AtherosclerosisTaishan Medical UniversityTaianChina
| | - Xia Lei
- Department of Cell BiologyState University of New York Downstate Medical CenterBrooklynNY
| | - Hui Jiang
- Department of Cell BiologyState University of New York Downstate Medical CenterBrooklynNY
| | - Zhiqiang Li
- Department of Cell BiologyState University of New York Downstate Medical CenterBrooklynNY
| | - John W. M. Creemers
- Laboratory of Biochemical NeuroendocrinologyDepartment of Human GeneticsHerestraat 49 bus 6023000 LeuvenBelgium
| | - Ming Zhang
- Department of Cell BiologyState University of New York Downstate Medical CenterBrooklynNY
| | - Shucun Qin
- Key Laboratory of Atherosclerosis in Universities of Shandong and Institute of AtherosclerosisTaishan Medical UniversityTaianChina
| | - Weijun Jin
- Department of Cell BiologyState University of New York Downstate Medical CenterBrooklynNY
| | - Xian‐Cheng Jiang
- Department of Cell BiologyState University of New York Downstate Medical CenterBrooklynNY
- Molecular and Cellular Cardiology ProgramVeterans Affair New York Harbor Healthcare SystemBrooklynNY
| |
Collapse
|
|
13
|
Jiang XC. Phospholipid transfer protein: its impact on lipoprotein homeostasis and atherosclerosis. J Lipid Res 2018; 59:764-771. [PMID: 29438986 DOI: 10.1194/jlr.r082503] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Revised: 01/10/2018] [Indexed: 12/25/2022] Open
Abstract
Phospholipid transfer protein (PLTP) is one of the major modulators of lipoprotein metabolism and atherosclerosis development in humans; however, we still do not quite understand the mechanisms. In mouse models, PLTP overexpression induces atherosclerosis, while its deficiency reduces it. Thus, mouse models were used to explore the mechanisms. In this review, I summarize the major progress made in the PLTP research field and emphasize its impact on lipoprotein metabolism and atherosclerosis, as well as its regulation.
Collapse
Affiliation(s)
- Xian-Cheng Jiang
- Department of Cell Biology, Downstate Medical Center, State University of New York, Brooklyn, NY
| |
Collapse
|
|
14
|
Berezin AE. Cardiac biomarkers in diabetes mellitus: New dawn for risk stratification? Diabetes Metab Syndr 2017; 11 Suppl 1:S201-S208. [PMID: 28011232 DOI: 10.1016/j.dsx.2016.12.032] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Accepted: 12/12/2016] [Indexed: 12/21/2022]
Abstract
Type 2 diabetes mellitus (T2DM) remains a leading cause of cardiovascular (CV) events and diseases worldwide. The aim of the review is to summarize our knowledge regarding clinical implementation of the biomarker-based strategy of the CV risk assessment in T2DM patient population. There is large body of evidence regarding use of the cardiac biomarkers to risk stratification at higher CV risk individuals who belongs to general population and cohort with established CV disease. Although T2DM patients have higher incidence of macrovascular and microvascular CV complications than the general population, whether cardiac biomarkers would be effective to risk stratification of the T2DM is not fully understood. The role of natriuretic peptides, galectin-3, interleukins, growth differentiation factor-15, as well as biomarkers of endothelial dysfunction are widely discussed. In conclusion, future directions, which associate with discovering of novel biomarkers and their best combinations to provide additional predictive information beyond other traditional CV risk factors, are discussed.
Collapse
Affiliation(s)
- Alexander E Berezin
- Private Hospital "Vita-Center", Zaporozhye, Ukraine; Internal Medicine Department, Medical University of Zaporozhye, Ukraine.
| |
Collapse
|
|
15
|
Ljunggren SA, Helmfrid I, Norinder U, Fredriksson M, Wingren G, Karlsson H, Lindahl M. Alterations in high-density lipoprotein proteome and function associated with persistent organic pollutants. ENVIRONMENT INTERNATIONAL 2017; 98:204-211. [PMID: 27865523 DOI: 10.1016/j.envint.2016.11.008] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Revised: 10/16/2016] [Accepted: 11/05/2016] [Indexed: 06/06/2023]
Abstract
There is a growing body of evidence that persistent organic pollutants (POPs) may increase the risk for cardiovascular disease (CVD), but the mechanisms remain unclear. High-density lipoprotein (HDL) acts protective against CVD by different processes, and we have earlier found that HDL from subjects with CVD contains higher levels of POPs than healthy controls. In the present study, we have expanded analyses on the same individuals living in a contaminated community and investigated the relationship between the HDL POP levels and protein composition/function. HDL from 17 subjects was isolated by ultracentrifugation. HDL protein composition, using nanoliquid chromatography tandem mass spectrometry, and antioxidant activity were analyzed. The associations of 16 POPs, including polychlorinated biphenyls (PCBs) and organochlorine pesticides, with HDL proteins/functions were investigated by partial least square and multiple linear regression analysis. Proteomic analyses identified 118 HDL proteins, of which ten were significantly (p<0.05) and positively associated with the combined level of POPs or with highly chlorinated PCB congeners. Among these, cholesteryl ester transfer protein and phospholipid transfer protein, as well as the inflammatory marker serum amyloid A, were found. The serum paraoxonase/arylesterase 1 activity was inversely associated with POPs. Pathway analysis demonstrated that up-regulated proteins were associated with biological processes involving lipoprotein metabolism, while down-regulated proteins were associated with processes such as negative regulation of proteinases, acute phase response, platelet degranulation, and complement activation. These results indicate an association between POP levels, especially highly chlorinated PCBs, and HDL protein alterations that may result in a less functional particle. Further studies are needed to determine causality and the importance of other environmental factors. Nevertheless, this study provides a first insight into a possible link between exposure to POPs and risk of CVD.
Collapse
Affiliation(s)
- Stefan A Ljunggren
- Occupational and Environmental Medicine Center, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
| | - Ingela Helmfrid
- Occupational and Environmental Medicine Center, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
| | - Ulf Norinder
- Swedish Toxicology Sciences Research Center, Södertälje, Sweden.
| | - Mats Fredriksson
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
| | - Gun Wingren
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
| | - Helen Karlsson
- Occupational and Environmental Medicine Center, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
| | - Mats Lindahl
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
| |
Collapse
|
|
16
|
Novel Biomarkers at Risk Stratification of Diabetes Mellitus Patients. STEM CELLS IN CLINICAL APPLICATIONS 2017. [DOI: 10.1007/978-3-319-55687-1_6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
|
17
|
Effect of Phospholipid Transfer Protein on Cigarette Smoke Extract-Induced IL-8 Production in Human Pulmonary Epithelial Cells. Inflammation 2016; 39:1972-1980. [DOI: 10.1007/s10753-016-0432-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
|
18
|
Miao Z, Wang J, Wang F, Liu L, Ding H, Shi Z. Comparative proteomics of umbilical vein blood plasma from normal and gestational diabetes mellitus patients reveals differentially expressed proteins associated with childhood obesity. Proteomics Clin Appl 2016; 10:1122-1131. [PMID: 27381806 DOI: 10.1002/prca.201600046] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2016] [Revised: 06/11/2016] [Accepted: 06/30/2016] [Indexed: 12/12/2022]
Abstract
PURPOSE Offspring obesity is one of long-term complications of gestational diabetes mellitus (GDM). The aim of this study is to identify proteins differentially expressed in the umbilical vein blood plasma, which could become markers for early diagnosis of childhood obesity. EXPERIMENTAL DESIGN Umbilical vein plasma samples were collected from 30 control and 30 GDM patients in 2007-2008 whose offspring were suffering from obesity at 6-7 years old. Multiplexed isobaric tandem mass tag labeling combined with LC-MS/MS was used to identify differentially expressed proteins. Ingenuity pathway analysis was performed to identify canonical pathways, biological functions, and networks of interacting proteins. Western blotting was used to verify the expression of three selected proteins. RESULTS A total of 318 proteins were identified, of which 12 proteins were upregulated in GDM group while 24 downregulated. Lipid metabolism was the top category identified by ingenuity pathway analysis. Three randomly chosen proteins were validated by Western blotting, which were consistent with LC-MS. CONCLUSION There are significant differences of protein profile in the umbilical vein blood plasma between normal and GDM patients with obese offspring. The results indicate that a variety of proteins and biological mechanisms may contribute to childhood obesity.
Collapse
Affiliation(s)
- Zhijing Miao
- State Key Laboratory of Reproductive Medicine, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, China
| | - Jianqing Wang
- Yancheng No. 1 People's Hospital Affiliated to Nantong University, Nantong, China
| | - Fuqiang Wang
- State Key Laboratory of Reproductive Medicine, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, China
| | - Lan Liu
- State Key Laboratory of Reproductive Medicine, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, China
| | - Hongjuan Ding
- State Key Laboratory of Reproductive Medicine, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, China
| | - Zhonghua Shi
- State Key Laboratory of Reproductive Medicine, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, China
| |
Collapse
|
|
19
|
Engelmann J, Manuwald U, Rubach C, Kugler J, Birkenfeld AL, Hanefeld M, Rothe U. Determinants of mortality in patients with type 2 diabetes: a review. Rev Endocr Metab Disord 2016; 17:129-37. [PMID: 27068710 DOI: 10.1007/s11154-016-9349-0] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
UNLABELLED We aimed to review and summarize the evidence from accomplished trials analyzing factors influencing mortality in patients with T2DM and to provide some recommendations for targets and treatment in the European region. The following databases were searched for relevant trials: PubMed and the Cochrane Library. Of 3.806 citations, 134 trials met our inclusion criteria. RESULTS The reduction in lifetime for 65 + -years-old patients having less than 10 years T2DM amounts to 1.8 years. Having T2DM for more than 10 years lifetime will be reduced by 2.7 years. However, the lifetime shortening factor of T2DM will even be stronger for 40 + -years-old patients at onset. Males will lose 11.6 years of life and 18.6 QUALYs. T2DM among females will reduce life by 14 QUALYs by 22 years. From a statistical point of view, the highest mortality rate will occur in an over 55-years-old European smoking and non-compliant diabetic woman with alcohol abuse living in a rural area with a low level of education and a low socio-economic status. Furthermore, other co-morbidities such as cardiovascular diseases, gout, and depression affect mortality. Additionally, mortality will increase with a BMI over 35 and also with a BMI under 20-25. This refers to the obesity paradox indicating a higher mortality rate among normal weight patients with T2DM compared to overweight patients with T2DM. HbA1c-levels between 6.5 % and 7 % are associated with the lowest impact on mortality.
Collapse
Affiliation(s)
- Jana Engelmann
- Health Sciences/Public Health, Faculty of Medicine, TUD, Fetscherstraße 74, D-01307, Dresden, Germany
| | - Ulf Manuwald
- Health Sciences/Public Health, Faculty of Medicine, TUD, Fetscherstraße 74, D-01307, Dresden, Germany
| | - Constanze Rubach
- Health Sciences/Public Health, Faculty of Medicine, TUD, Fetscherstraße 74, D-01307, Dresden, Germany
| | - Joachim Kugler
- Health Sciences/Public Health, Faculty of Medicine, TUD, Fetscherstraße 74, D-01307, Dresden, Germany
| | - Andreas L Birkenfeld
- Medical Clinic III, University Clinic, Faculty of Medicine, TUD, Fetscherstraße 74, D-01307, Dresden, Germany
- Study Center Prof. Hanefeld, Research for Metabolic Vascular Syndrome, GWT-TUD GmbH, Fiedlerstraße 34, D-01307, Dresden, Germany
| | - Markolf Hanefeld
- Study Center Prof. Hanefeld, Research for Metabolic Vascular Syndrome, GWT-TUD GmbH, Fiedlerstraße 34, D-01307, Dresden, Germany
| | - Ulrike Rothe
- Health Sciences/Public Health, Faculty of Medicine, TUD, Fetscherstraße 74, D-01307, Dresden, Germany.
| |
Collapse
|
|
20
|
Berezin AE. Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15. Diabetes Metab Syndr 2016; 10:S154-S157. [PMID: 26482961 DOI: 10.1016/j.dsx.2015.09.016] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Accepted: 09/27/2015] [Indexed: 12/23/2022]
Abstract
Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine, which belongs to super family of the transforming growth factor beta. GDF-15 is widely presented in the various cells (macrophages, vascular smooth muscle cells, adipocytes, cardiomyocytes, endothelial cells, fibroblasts), tissues (adipose tissue, vessels, tissues of central and peripheral nervous system) and organs (heart, brain, liver, placenta) and it plays an important role in the regulation of the inflammatory response, growth and cell differentiation. Elevated GDF-15 was found in patients with established CV diseases including hypertension, stable coronary artery disease, acute coronary syndrome, myocardial infarction, ischemic and none ischemic-induced cardiomyopathies, heart failure, atrial fibrillation, as well as stroke, type two diabetes mellitus (T2DM), chronic kidney disease, infection, liver cirrhosis, malignancy. Therefore, aging, smoking, and various environmental factors, i.e. chemical pollutants are other risk factors that might increase serum GDF-15 level. Although GDF-15 has been reported to be involved in energy homoeostasis and weight loss, to have anti-inflammatory properties, and to predict CV diseases and CV events in general or established CV disease population, there is no large of body of evidence regarding predictive role of elevated GDF-15 in T2DM subjects. The mini review is clarified the role of GDF-15 in T2DM subjects.
Collapse
Affiliation(s)
- Alexander E Berezin
- Internal Medicine Department, State Medical University, 26, Mayakovsky av., Zaporozhye 69035, Ukraine.
| |
Collapse
|